Natera (NASDAQ:NTRA) CFO Sells $84,952.83 in Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 317 shares of the firm’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $267.99, for a total transaction of $84,952.83. Following the completion of the transaction, the chief financial officer directly owned 52,115 shares in the company, valued at approximately $13,966,298.85. This represents a 0.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Michael Burkes Brophy also recently made the following trade(s):

• On Tuesday, August 4th, Michael Burkes Brophy sold 478 shares of Natera stock. The shares were sold at an average price of $274.22, for a total transaction of $131,077.16.
• On Wednesday, July 29th, Michael Burkes Brophy sold 1,863 shares of Natera stock. The stock was sold at an average price of $249.38, for a total transaction of $464,594.94.
• On Tuesday, July 28th, Michael Burkes Brophy sold 2,419 shares of Natera stock. The shares were sold at an average price of $253.96, for a total value of $614,329.24.
• On Monday, July 27th, Michael Burkes Brophy sold 782 shares of Natera stock. The shares were sold at an average price of $260.49, for a total value of $203,703.18.

Natera Price Performance

Shares of NTRA opened at $322.10 on Friday. The stock’s 50-day moving average is $254.03 and its two-hundred day moving average is $223.79. The stock has a market cap of $46.13 billion, a PE ratio of -236.84 and a beta of 1.51. Natera, Inc. has a 12 month low of $149.38 and a 12 month high of $323.01.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.02. Natera had a negative return on equity of 11.82% and a negative net margin of 7.11%.The company had revenue of $752.75 million during the quarter, compared to the consensus estimate of $661.24 million. During the same quarter in the prior year, the business earned ($0.74) earnings per share. The company’s revenue was up 37.7% compared to the same quarter last year. On average, research analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on NTRA. The Goldman Sachs Group assumed coverage on shares of Natera in a research note on Friday, June 5th. They set a “neutral” rating and a $245.00 price objective on the stock. Wolfe Research assumed coverage on shares of Natera in a report on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 price target for the company. Canaccord Genuity Group set a $375.00 price target on shares of Natera in a research note on Friday. JPMorgan Chase & Co. boosted their price objective on shares of Natera from $315.00 to $360.00 and gave the stock an “overweight” rating in a report on Friday. Finally, UBS Group set a $260.00 price objective on shares of Natera in a report on Wednesday, June 24th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $299.65.

Natera News Roundup

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Revenue significantly exceeded expectations. Natera generated $752.8 million in second-quarter revenue, up 37.7% year over year and well above the $661.2 million analyst consensus. Gross margin also improved to 64.5% from 63.4% a year earlier. Natera Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The quarterly loss narrowed. Natera reported a loss of $0.47 per share, compared with a $0.74-per-share loss in the prior-year quarter, and better than the $0.49 loss expected by analysts. The result suggests continued operating improvement despite the company remaining unprofitable. Natera Reports Q2 Loss and Beats Revenue Estimates
• Positive Sentiment: Management raised its fiscal 2026 revenue outlook to approximately $2.9 billion, above the roughly $2.8 billion consensus estimate. The higher guidance points to sustained momentum across Natera’s reproductive health, oncology, and transplant-testing businesses.
• Positive Sentiment: JPMorgan raised its price target on NTRA from $315 to $360 and maintained an “overweight” rating, signaling that the bank sees additional upside after the earnings beat. Benzinga
• Positive Sentiment: Natera submitted its Signatera bladder-cancer test to Japan’s PMDA for approval as a companion diagnostic. Clearance could expand the company’s international oncology market and create another source of long-term growth. Natera Submits Signatera to Japan’s PMDA
• Neutral Sentiment: Several executives sold shares under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. Because the sales were relatively small compared with their remaining holdings and were not discretionary open-market disposals, they provide limited negative information.
• Negative Sentiment: Natera remains unprofitable, and its very high valuation leaves the shares vulnerable to profit-taking if growth slows or future results fail to exceed elevated expectations. Commentary identifying NTRA as entering a potential profit-taking zone highlights this near-term risk. IBD 50 Stock Natera Profit-Taking Zone

Hedge Funds Weigh In On Natera

Several institutional investors and hedge funds have recently made changes to their positions in the business. Trust Co. of Vermont acquired a new stake in shares of Natera during the second quarter worth approximately $26,000. Reflection Asset Management acquired a new stake in Natera in the fourth quarter valued at $29,000. Elevation Wealth Partners LLC acquired a new stake in Natera in the second quarter valued at $30,000. Palladiem LLC bought a new position in Natera during the 4th quarter valued at $31,000. Finally, Horizon Investments LLC bought a new position in Natera during the 3rd quarter valued at $32,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.